Capula Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$697K Buy
5,000
+100
+2% +$14K 0.01% 439
2025
Q4
$601K Sell
4,900
-11,700
-70% -$1.42M ﹤0.01% 357
2025
Q3
$1.84M Buy
16,600
+14,000
+538% +$1.59M 0.01% 263
2025
Q2
$288K Buy
2,600
+400
+18% +$42.6K ﹤0.01% 303
2025
Q1
$247K Buy
+2,200
New +$227K ﹤0.01% 462
2023
Q3
Sell
-4,100
Closed -$316K 570
2023
Q2
$316K Sell
4,100
-54,500
-93% -$4.35M 0.01% 358
2023
Q1
$4.86M Sell
58,600
-208,800
-78% -$17.3M 0.06% 241
2022
Q4
$23M Sell
267,400
-97,000
-27% -$7.68M 0.31% 87
2022
Q3
$22.5M Buy
364,400
+292,400
+406% +$18.4M 0.3% 87
2022
Q2
$4.45M Buy
+72,000
New +$4.46M 0.08% 209
2021
Q4
Sell
-22,900
Closed -$1.6M 426
2021
Q3
$1.6M Buy
+22,900
New +$1.61M 0.02% 442
2021
Q2
Sell
-147,500
Closed -$9.53M 814
2021
Q1
$9.53M Sell
147,500
-2,500
-2% -$161K 0.19% 136
2020
Q4
$8.74M Sell
150,000
-33,700
-18% -$2.03M 0.43% 58
2020
Q3
$11.6M Buy
183,700
+50,500
+38% +$3.5M 1.48% 22
2020
Q2
$10.2M Buy
133,200
+84,800
+175% +$6.5M 0.36% 69
2020
Q1
$3.62M Sell
48,400
-50,000
-51% -$3.45M 0.13% 196
2019
Q4
$6.39M Buy
98,400
+48,400
+97% +$3.15M 0.14% 148
2019
Q3
$3.17M Buy
+50,000
New +$3.27M 0.07% 193

Other funds holding GILD

Capula Management's GILD Position: Q4 2025 in Review

Capula Management sold out of Gilead Sciences (GILD) in Q4 2025, closing a stake of 6,009 shares — an estimated $730K sold.

Capula Management first reported a position in GILD in Q3 2019 and held it in 16 quarters. The position peaked at $7.97M in Q3 2020. 2,215 funds tracked by Wall St. Rank hold GILD as of Q4 2025.

  • Capula Management reported no remaining Gilead Sciences position as of Q4 2025 after selling out during the quarter.
  • Capula Management sold 6,009 Gilead Sciences shares in Q4 2025, an estimated $730K.
  • Capula Management first reported a position in Gilead Sciences in Q3 2019 and held it in 16 quarters.
  • Capula Management's Gilead Sciences position peaked at $7.97M in Q3 2020.
  • 2,215 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2025.

Based on Capula Management's 13F filing for Q4 2025, filed 13 Feb 2026.